Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ultrasound clue vanishes days after steroids start in artery disease

NCT ID NCT07060274

Knowledge-focused Sponsor: Centre Hospitalier le Mans Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tracks how fast the 'halo sign' — a key ultrasound marker of inflamed arteries — disappears after starting steroid treatment in people with giant cell arteritis, a rare disease that can cause blindness. Researchers will scan the temporal arteries of 64 newly diagnosed patients before steroids and again at 3, 7, and 15 days. The goal is to find the best time window for accurate diagnosis using this quick, non-invasive test.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
corticosteroid therapy (standard treatment for giant cell arteritis)
What this could lead to
If successful, this could help doctors know the best window to perform temporal artery ultrasound for diagnosing giant cell arteritis, potentially speeding up treatment and preventing blindness.
What could go wrong
This is a small observational study, not a treatment trial. The findings may not apply to all patients or change current guidelines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 64 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 50 and over * Without legal protection. * Meeting GCA classification criteria as defined by ACR 2022 with the presence of a halo sign-unilateral or bilateral-on Doppler ultrasound of the temporal artery. * Newly diagnosed with an indication for corticosteroid treatment. * Have not yet received corticosteroid treatment for GCA. * No contraindication to corticosteroid treatment. * Person affiliated with or benefiting from a social security scheme. * Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination necessary for the research). Exclusion Criteria: * Patients with a relapse of Giant Cell Arteritis (GCA). * Patients who have previously undergone a temporal artery biopsy (TAB), including for other reasons. * Patients who have received oral corticosteroid treatment in the past month or are currently on corticosteroid therapy (excluding hydrocortisone or local corticosteroids). * Patients with other types of vasculitis that may constitute a differential diagnosis: presence of antibodies against the cytoplasm of neutrophils (ANCA), positive syphilis serology, positivity of an IGRA test (Interferon Gamma Release Assay). * Patients having received immunosuppressive treatment or biotherapy in the month prior to inclusion. If the patient's condition warrants the use of biotherapy or immunosuppressive treatment, its initiation will be delayed until after Day 7 to avoid interfering with the Doppler procedure.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Doppler ultrasound are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Giant Cell Arteritis temporal arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Doppler ultrasound Giant cell arteritis (GCA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Caen Normandie

    NOT_YET_RECRUITING

    Caen, 14000, France

  • CHU Dijon - Hôpital François Mitterrand

    NOT_YET_RECRUITING

    Dijon, 21000, France

  • CHU Nantes

    RECRUITING

    Nantes, 44000, France

  • CHU d'Angers

    RECRUITING

    Angers, 49100, France

  • Centre Hospitalier du Mans

    RECRUITING

    Le Mans, Sarthe, 72000, France

  • Groupe hospitalier La Rochelle-Ré-Aunis

    RECRUITING

    La Rochelle, 17000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.